TheraRadar

Helixmith

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 11/14/2021

15
Total Trials
6
Phase 3
10
Phase 2
0
Recruiting
182
Score

Pipeline by Phase

Phase 3
6
Phase 2
10
Phase 1
4

Therapeutic Focus

Diabetic Neuropathy, Painful Amyotrophic Lateral Sclerosis Painful Diabetic Neuropathy Diabetic Peripheral Neuropathy Foot Ulcer, Diabetic

Clinical Trials (15)

NCT04055090 Phase 3 COMPLETED

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Started: 2/4/2019

NCT04469270 Phase 3 COMPLETED

Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

Started: 11/20/2020

NCT04873232 Phase 3 COMPLETED

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Started: 5/17/2021

NCT02563522 Phase 3 TERMINATED

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

Started: 6/27/2017

NCT02427464 Phase 3 COMPLETED

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Started: 4/1/2016

NCT01064440 Phase 2 COMPLETED

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Started: 7/9/2010

NCT04632225 Phase 2 COMPLETED

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Started: 3/9/2021

NCT01475786 Phase 2 COMPLETED

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Started: 8/1/2012

NCT05176093 Phase 2 COMPLETED

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Started: 11/14/2021

NCT05552625 Phase 2 WITHDRAWN

The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19

Started: 5/6/2021

NCT03404024 Phase 2 WITHDRAWN

Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea

Started: 1/25/2018

NCT01002235 Phase 1 COMPLETED

Gene Therapy for Painful Diabetic Neuropathy

Started: 2/1/2010

NCT02039401 Phase 1 COMPLETED

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

Started: 3/11/2014

NCT05361031 Phase 1 COMPLETED

The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

Started: 9/21/2020

NCT01002495 Phase 1 WITHDRAWN

Gene Therapy for the Treatment of Chronic Stable Angina

Started: 3/1/2015

Drug Candidates

Long-Term Follow-Up of Patients who Received Placebo Engensis Placebo Engensis (VM202) Low Dose VM202 High Dose VM202 VM202 Low Dose: 16 mg Engensis (VM202) High Dose: 32 mg Engensis (VM202) TADIOS
Activity Status: Stale
Last Trial Started: 11/14/2021
Last Trial Ended: 8/23/2024
Trials (12 months): 0
Completed Trials: 11
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.